ZyVersa Therapeutics Files 8-K
Ticker: ZVSA · Form: 8-K · Filed: Jul 28, 2025 · CIK: 1859007
| Field | Detail |
|---|---|
| Company | Zyversa Therapeutics, Inc. (ZVSA) |
| Form Type | 8-K |
| Filed Date | Jul 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-statements
TL;DR
ZyVersa filed an 8-K on 7/28 for events on 7/25. Standard reporting.
AI Summary
ZyVersa Therapeutics, Inc. filed an 8-K on July 28, 2025, reporting other events and financial statements as of July 25, 2025. The company, formerly Larkspur Health Acquisition Corp., is incorporated in Delaware and has its principal executive offices in Weston, Florida.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies to keep investors informed.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain significant new information that would immediately impact the company's risk profile.
Key Players & Entities
- ZyVersa Therapeutics, Inc. (company) — Registrant
- Larkspur Health Acquisition Corp. (company) — Former company name
- July 25, 2025 (date) — Date of earliest event reported
- July 28, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for ZyVersa Therapeutics, Inc.?
The filing reports "Other Events" and "Financial Statements and Exhibits" as of July 25, 2025.
When was this 8-K report filed with the SEC?
The report was filed on July 28, 2025.
What was ZyVersa Therapeutics, Inc. formerly known as?
The company was formerly known as Larkspur Health Acquisition Corp.
In which state is ZyVersa Therapeutics, Inc. incorporated?
ZyVersa Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for ZyVersa Therapeutics, Inc.?
The principal executive offices are located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 28, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).